HOUSE_OVERSIGHT_024011.jpg
841 KB
Extraction Summary
0
People
3
Organizations
0
Locations
0
Events
1
Relationships
3
Quotes
Document Information
Type:
Table of contents / investment memorandum
File Size:
841 KB
Summary
This document is a Table of Contents for a confidential investment memorandum or offering document related to New Leaf Venture Partners and the healthcare sector. It outlines sections regarding historical performance, investment strategy, and an ongoing relationship with Sprout Funds. The page bears a House Oversight Bates stamp, indicating it is part of a congressional investigation.
Organizations (3)
| Name | Type | Context |
|---|---|---|
| New Leaf Venture Partners |
Subject of Section V regarding investment strategy
|
|
| Sprout Funds |
Subject of Section VII regarding ongoing relationship
|
|
| House Oversight Committee |
Implied by Bates stamp 'HOUSE_OVERSIGHT_024011'
|
Relationships (1)
Section VII: 'Ongoing Relationship With Sprout Funds'
Full Extracted Text
Complete text extracted from the document (1,930 characters)
TABLE OF CONTENTS
I. Executive Summary....................................................................................................................... 1
II. The Team ...................................................................................................................................... 11
III. Summary of Historical Investment Performance.................................................................. 18
IV. Opportunity In The Healthcare Sector................................................................................... 24
V. New Leaf Venture Partners Investment Strategy .................................................................... 31
VI. Deal Sourcing & Investment Process ...................................................................................... 43
VII. Ongoing Relationship With Sprout Funds............................................................................. 45
VIII. Summary of Partnership Terms ............................................................................................ 46
IX. Certain Investment Considerations ......................................................................................... 58
X. Certain Tax and ERISA Considerations..................................................................................... 73
XI. Certain Legal & Regulatory Considerations............................................................................ 85
XII. Additional Information............................................................................................................. 88
XIII. Appendices .............................................................................................................................. 89
XIV. Certain Offering Notices ....................................................................................................... 100
II. The Team ...................................................................................................................................... 11
III. Summary of Historical Investment Performance.................................................................. 18
IV. Opportunity In The Healthcare Sector................................................................................... 24
V. New Leaf Venture Partners Investment Strategy .................................................................... 31
VI. Deal Sourcing & Investment Process ...................................................................................... 43
VII. Ongoing Relationship With Sprout Funds............................................................................. 45
VIII. Summary of Partnership Terms ............................................................................................ 46
IX. Certain Investment Considerations ......................................................................................... 58
X. Certain Tax and ERISA Considerations..................................................................................... 73
XI. Certain Legal & Regulatory Considerations............................................................................ 85
XII. Additional Information............................................................................................................. 88
XIII. Appendices .............................................................................................................................. 89
XIV. Certain Offering Notices ....................................................................................................... 100
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024011
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document